ArticleLeukemia2013
Altered miRNA and gene expression in acute myeloid leukemia with complex karyotype identify networks of prognostic relevance.
Article in Leukemia, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 48 citations in OpenAlex.
- Molecular dissection of valproic acid effects in acute myeloid leukemia identifies predictive networks.Epigenetics · 2016Trial
- Role of MicroRNAs in Acute Myeloid Leukemia.Genes · 2025Review
- A novel therapeutic strategy: the significance of exosomal miRNAs in acute myeloid leukemia.Medical oncology (Northwood, London, England) · 2024Review
- Bone marrow microRNA-34a is a good indicator for response to treatment in acute myeloid leukemia.Oncology research · 2024Article
- Small Non-Coding RNAs in Leukemia.Cancers · 2022Review
- Circular RNA ATAD1 is upregulated in acute myeloid leukemia and promotes cancer cell proliferation by downregulating miR-34b via promoter methylation.Oncology letters · 2021Article
- Deregulated expression of circular RNAs in acute myeloid leukemia.Blood advances · 2021Article
- Targeting microRNA in hematologic malignancies.Current opinion in oncology · 2020Review
- miR-100-5p Inhibits Malignant Behavior of Chordoma Cells by Targeting IGF1R.Cancer management and research · 2020Article
- Circular RNAs in leukemia.Aging · 2019Review
- Identification of serum miR-34a as a potential biomarker in acute myeloid leukemia.Cancer biomarkers : section A of Disease markers · 2018Article
- miR-126 promotes the growth and proliferation of leukemia stem cells by targeting DNA methyltransferase 1.International journal of clinical and experimental pathology · 2018Article
- Chromothripsis is linked toHaematologica · 2018Article
- Circular RNAs of the nucleophosmin (NPM1) gene in acute myeloid leukemia.Haematologica · 2017Article
- Prospective identification of resistance mechanisms to HSP90 inhibition in KRAS mutant cancer cells.Oncotarget · 2017Article
- microRNAs and Acute Myeloid Leukemia Chemoresistance: A Mechanistic Overview.Frontiers in oncology · 2017Review
- Prognostic nomogram for previously untreated adult patients with acute myeloid leukemia.Oncotarget · 2016Article
- Article
- Clinical significance of microRNAs in chronic and acute human leukemia.Molecular cancer · 2016Review
- miR-34b Targets HSF1 to Suppress Cell Survival in Acute Myeloid Leukemia.Oncology research · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recently, the p53-miR-34a network has been identified to have an important role in tumorigenesis. As in acute myeloid leukemia with complex karyotype (CK-AML) TP53 alterations are the most common known molecular lesion, we further analyzed the p53-miR-34a axis in a large cohort of CK-AML with known TP53 status (TP53(altered), n=57; TP53(unaltered), n=31; altered indicates loss and/or mutation of TP53). Profiling microRNA (miRNA) expression delineated TP53 alteration-associated miRNA profiles, and identified miR-34a and miR-100 as the most significantly down- and upregulated miRNA, respectively. Moreover, we found a distinct miR-34a expression-linked gene expression profile enriched for genes belonging to p53-associated pathways, and implicated in cell cycle progression or apoptosis. Clinically, low miR-34a expression and TP53 alterations predicted for chemotherapy resistance and inferior outcome. Notably, in TP53(unaltered) CK-AML, high miR-34a expression predicted for inferior overall survival (OS), whereas in TP53(biallelic altered) CK-AML, high miR-34a expression pointed to better OS. Thus, detailed molecular profiling links impaired p53 to decreased miR-34a expression, but also identifies p53-independent miR-34a induction mechanisms as shown in TP53(biallelic altered) cell lines treated with 15-deoxy-Δ(12,14)-prostaglandin. An improved understanding of this mechanism might provide novel therapeutic options to restore miR-34a function and thereby induce cell cycle arrest and apoptosis in TP53(altered) CK-AML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.